Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesPhase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy
Journal of Clinical Oncology, 10/08/09
Herrstedt J et al. – All casopitant regimens studied were more effective than the control regimen. Casopitant was generally well tolerated.
Methods- Multinational, randomized, double-blind, parallel-group, placebo-controlled clinical trial
- Predominantly female patients (98%) diagnosed with breast cancer (96%) who were chemotherapy-naïve and scheduled to receive an anthracycline and cyclophosphamide (AC) –based regimen enrolled
- All patients received dexamethasone 8 mg intravenously (IV) on day 1 and oral ondansetron 8 mg twice daily on days 1 to 3
- Patients randomly assigned to control arm (placebo), a single oral dose casopitant arm (150 mg orally [PO] on day 1), a 3-day oral casopitant arm (150 mg PO on day 1 plus 50 mg PO on days 2 to 3), or a 3-day IV/oral casopitant arm (90 mg IV on day 1 plus 50 mg PO on days 2 to 3)
- The primary end point was proportion of patients achieving complete response (no vomiting/retching or rescue medications) in first 120 hours after the initiation of MEC
- Significantly greater proportion of patients in single-dose oral casopitant arm, 3-day oral casopitant arm, and 3-day IV/oral casopitant arm achieved complete response versus control
- Study did not demonstrate reduced proportion of patients with nausea or significant nausea in those receiving casopitant
- Adverse events were balanced among study arms
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Activity of fulvestrant in HER2-overexpressing advanced breast cancer
Annals of Oncology, 11/06/09
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer
Journal of Clinical Oncology, 11/02/09
Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia
Journal of Clinical Oncology, 11/09/09
Today in Side Effects...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes
Journal of Clinical Oncology, 11/12/09
Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy
Supportive Care in Cancer, 11/06/09
Incidence and Correlates of Radiation Dermatitis in Children and Adolescents Receiving Radiation Therapy for the Treatment of Paediatric Sarcomas
Clinical Oncology, 11/12/09
Sponsor
Article Search
Sponsor
Sponsor